German Scientists Discover Antibiotic in Human Nose

This undated photo provided by the Center for Disease Control (CDC) shows plates of Methicillin-Resistant Staphylococcus Aureus (MRSA) in CDC’s healthcare-associated infections laboratory. (AP)
This undated photo provided by the Center for Disease Control (CDC) shows plates of Methicillin-Resistant Staphylococcus Aureus (MRSA) in CDC’s healthcare-associated infections laboratory. (AP)
TT

German Scientists Discover Antibiotic in Human Nose

This undated photo provided by the Center for Disease Control (CDC) shows plates of Methicillin-Resistant Staphylococcus Aureus (MRSA) in CDC’s healthcare-associated infections laboratory. (AP)
This undated photo provided by the Center for Disease Control (CDC) shows plates of Methicillin-Resistant Staphylococcus Aureus (MRSA) in CDC’s healthcare-associated infections laboratory. (AP)

The Nature Microbiology journal reported that scientists at the German University of Tübingen have discovered a novel antibiotic substance from the human nose that can be used against pathogenic bacteria.

“Named epifadin, the molecule is produced from specific strains of the bacterial species Staphylococcus epidermidis, which occur on the mucous membrane of the inside wall of the nose,” the journal added.

Epifadin constitutes a new, previously unknown class of antimicrobial compounds that kills microorganisms and could be used as a lead structure for the development of novel antibiotics.

Epifadin not only works against the bacteria that are locally in competition with Staphylococcus epidermidis, it is also effective against bacteria from other habitats such as the intestine and certain fungi.

The researchers found that it is especially effective against the potential pathogens Staphylococcus aureus, a hospital-acquired infection which is particularly dangerous in antibiotic-resistant form (MRSA). But, more research is needed to discover whether epifadin or its derivates can be used for therapy.



Rwanda and WHO Declare End of Marburg Outbreak after No New Cases Reported

In this Oct. 8, 2014 photo, a medical worker from the Infection Prevention and Control unit wearing full protective equipment carries a meal to an isolation tent housing a man being quarantined after coming into contact in Uganda with a carrier of the Marburg Virus, at the Kenyatta National Hospital in Nairobi, Kenya. (AP)
In this Oct. 8, 2014 photo, a medical worker from the Infection Prevention and Control unit wearing full protective equipment carries a meal to an isolation tent housing a man being quarantined after coming into contact in Uganda with a carrier of the Marburg Virus, at the Kenyatta National Hospital in Nairobi, Kenya. (AP)
TT

Rwanda and WHO Declare End of Marburg Outbreak after No New Cases Reported

In this Oct. 8, 2014 photo, a medical worker from the Infection Prevention and Control unit wearing full protective equipment carries a meal to an isolation tent housing a man being quarantined after coming into contact in Uganda with a carrier of the Marburg Virus, at the Kenyatta National Hospital in Nairobi, Kenya. (AP)
In this Oct. 8, 2014 photo, a medical worker from the Infection Prevention and Control unit wearing full protective equipment carries a meal to an isolation tent housing a man being quarantined after coming into contact in Uganda with a carrier of the Marburg Virus, at the Kenyatta National Hospital in Nairobi, Kenya. (AP)

The World Health Organization and the Rwandan government on Friday declared the outbreak in Rwanda of the Ebola-like Marburg fever over after no new cases were registered in recent weeks.

The country first declared the outbreak on Sept. 27 and reported a total of 15 deaths and 66 cases, with the majority of those affected healthcare workers who handled the first patients.

Without treatment, Marburg can be fatal in up to 88% of people who fall ill with the disease. Symptoms include fever, muscle pains, diarrhea, vomiting and, in some cases, death through extreme blood loss.

There is no authorized vaccine or treatment for Marburg, though Rwanda received hundreds of doses of a vaccine under trial in October.

An outbreak is considered over after 42 days — two 21-day incubation cycles of the virus — elapsed without registering new cases and all existing cases test negative.

Rwanda discharged the last Marburg patient on Nov. 8 and had reported no new confirmed cases since Oct. 30.

However, WHO officials and Rwanda's Health Minister Dr. Sabin Nzanzimana on Friday said risks remain and that people should stay vigilant.

“We believe it’s not completely over because we still face risks, especially from bats. We are continuing to build new strategies, form new health teams, and deploy advanced technologies to track their movements, understand their behavior, and monitor who is interacting with them,” the minister announced during a press conference in the capital, Kigali.

Like Ebola, the Marburg virus is believed to originate in fruit bats and spreads between people through close contact with the bodily fluids of infected individuals or with surfaces, such as contaminated bed sheets.

“I thank the government of Rwanda, its leadership and Rwandans in general for the strong response to achieve this success but the battle continues,” said the WHO representative in Rwanda, Dr. Brain Chirombo.

Marburg outbreaks and individual cases have in the past been recorded in Tanzania, Equatorial Guinea, Angola, Congo, Kenya, South Africa, Uganda and Ghana.

The virus was first identified in 1967 after it caused simultaneous outbreaks of disease in laboratories in the German city of Marburg and in Belgrade in the former Yugoslavia. Seven people died after being exposed to the virus while conducting research on monkeys.